Venetoclax tablets

Venetoclax tablets are a B-cell lymphoma factor-2 inhibitor with venetoclax as the main ingredient. They are generally not used alone in clinical practice, but are mainly used in combination with azacitidine to treat adult acute myeloid leukemia. This product is suitable for:
Acute myeloid leukemia patients who are not suitable for intensive induction chemotherapy due to comorbidities. Acute myeloid leukemia is the most common acute leukemia in adults. The primitive white blood cells in the patient’s body proliferate clonally, leading to abnormal white blood cells, red blood cells and platelets, disrupting the growth of normal cells. It is extremely invasive and difficult to treat, and the survival rate of patients is extremely low. This product can be used to treat adult acute myeloid leukemia patients who are intolerant to intensive chemotherapy.
Newly diagnosed adult acute myeloid leukemia patients aged 75 years and above. Venetoclax tablets combined with azacitidine can achieve rapid and lasting remission rates in elderly acute myeloid leukemia patients who do not meet the conditions for intensive chemotherapy.